Given the molecular findings (CALR mutation + NF1::SCAMP5 fusion) and MF-1 fibrosis, the patient was provisionally classified as “MPN with features overlapping early-stage PMF”, though the megakaryocyte-poor histology suggests a potential novel subtype requiring further validation. This evidence concerns the gene CALR and myeloproliferative disorder.